Page 1

● ● Johnson & Johnson Strong sales growth of 27.1 % to $ 23.3 Billion in Second Quarter 2021 with operational growth of 23.0 % * and adjusted operational growth of 23.8 % * EPS of $ 2.35 increased 72.8 % in Second Quarter 2021 and adjusted EPS of $ 2.48 increased 48.5 % * • Company increasing 2021 Full - Year guidance for sales and EPS Johnson & Johnson Reports Q2 2021 Results : New Brunswick , N.J. ( July 21 , 2021 ) -Johnson & Johnson ( NYSE : JNJ ) today announced results for second - quarter . " Our second - quarter results showcase Johnson & Johnson's diversified portfolio , driven by strong sales and earnings growth across our Medical Device , Consumer Health and Pharmaceutical businesses , ” said Alex Gorsky , Chairman and Chief Executive Officer . " I'm so proud of our 136,000 colleagues who remain focused on delivering our medicines and products to patients and consumers around the world , in addition to advancing our pipeline with new product launches and regulatory submissions . These accomplishments exemplify our commitment to advancing transformational innovations that improve the health of people and communities everywhere while continuing to deliver long - term value to all of our stakeholders . " OVERALL FINANCIAL RESULTS Q2 ( $ in Millions , except EPS ) Reported Sales Q2 Net Earnings EPS ( diluted ) Non - GAAP * ( $ in Millions , except EPS ) 1,2 Operational Sales 1,3 Adjusted Operational Sales 1,4 Adjusted Net Earnings ¹ , 1,4 Adjusted EPS ( diluted ) ¹ $ $ 2021 23,312 $ 6,278 2.35 $ 2021 6,625 2.48 $ 2020 18,336 3,626 1.36 2020 FOR IMMEDIATE RELEASE 4,446 1.67 % Change 27.1 % 73.1 72.8 % % Change 23.0 % 23.8 49.0 48.5 % 1 Non - GAAP financial measure ; refer to reconciliations of non - GAAP financial measures included in accompanying schedules 2 Excludes the impact of translational currency 3 Excludes the net impact of acquisitions and divestitures and translational currency 4 Excludes intangible amortization expense and special items